WHC is still in active development. Read this to understand our approach.
depiction of RUOKEQAAGRXIBM-UHFFFAOYSA-N.svg
isomerdesign

Rasagiline

Verificar en isomerdesign

pubchem

Rasagiline

Verificar en pubchem

drugmap

Rasagiline

Verificar en drugmap

drugmap

Rasagiline

Verificar en drugmap

wiki

Rasagiline

Verificar en wiki

Data

InChI: InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2

Sinónimos: ZINC19875504,1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)-,1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R), KS-00000LL3, AS-32581, V3968,003N66TS6T,SMR002533187,NSC789038,Q420685, FT-0674331,(1R)-N-prop-2-ynylindan-1-amine, AC1NRD1Z,CHEMBL887, CHEMBL1235738,(R)-2,3-dihydro-N-2-propynyl-1H-inden-1-amine, AKOS024256741,(1R)-N-propargylindan-1-amine,Rasagiline,A2916,D08469, (1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine,185517-74-2,(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine, Azilect (TN), ZINC19875505,SR-00000006359-3,136236-51-6, TC-111987, FT-0694134,N-propargyl-1-(R)aminoindan,MLS006012042, Rasagiline [INN],TV-1030, AJ-75608,Azilect (TN), BDBM11000,RASAGILINE [EMA EPAR], HY-14200, TVP1022, (1S)-N-methyl-N-prop-2-ynyl-indan-1-amine,CCG-213034,RASAGILINE [VANDF],Rasagiline (USAN/INN),(R)-(+)-Rasagiline,SR-00000006359,CHEBI:63620, N-propargyl-1-(s)aminoindan, J-500397, SCHEMBL332967,RASAGILINE [HSDB],HMS3715L12,1H-INDEN-1-AMINE, 2,3-DIHYDRO-N-2-PROPYNYL-, (R)-, (S)-N-2-propynyl-1-indanamine, MolPort-006-666-243,AM84542,s5795,1-Indanamine, N-2-propynyl-, (R)-,EN300-150047,NSC 759639,1H-INDEN-1-AMINE, 2,3-DIHYDRO-N-2-PROPYN-1-YL-, (1R)-,AB01562963_02, CJ-16483,NSC-759639,(R)-N-(2-Propynyl)-2,3-dihydroinden-1-amine,rasagiline, (S)-Rasagiline,HSDB 7699, (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine, (S)-N-(2-Propynyl)-2,3-dihydroinden-1-amine, 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R),(1R)-N-(prop-2-yn-1-yl)indan-1-amine, FCH907116,HY-14605A, TV-1022, DB03894,MFCD00866571, (R)-N-2-Propynyl-1-indanamine,Azilect,UNII-003N66TS6T,NSC759639,DTXSID3041112,RAS,(R)-N-(prop-2-ynyl)-2,3-dihydro-1H-inden-1-amine,AKOS006271452,NSC-789038,RASAGILINE [ORANGE BOOK], RUOKEQAAGRXIBM-LBPRGKRZSA-N,RASAGILINE [MI], AB0052190,BDBM10989, TVP1022, &gt,FS-3130,DB01367,SCHEMBL2029054,AC-723, N-PROPARGYL-1(S)-AMINOINDAN,TVP1012,(R)-Indan-1-yl-prop-2-ynyl-amine,AB01562963_01, Rasagiline (INN), ANW-23242,TV 1030,Rasagiline [INN],RASAGILINE [WHO-DD],(1R)-2,3-DIHYDRO-N-2-PROPYN-1-YL-1H-INDEN-1-AMINE,Rasagiline [USAN],(R)-N-(prop-2-ynyl)-2,3-dihydro-1H-inden-1-amine;(R)-N-(2-Propynyl)-2,3-dihydroinden-1-amine,HMS3886N03,Rasagiline [USAN:INN],DB-001111, S-PAI,HMS3264K12, AC-14138,Pharmakon1600-01502333,N-Propargyl-1(S)-Aminoindan,1204184-69-9,AKOS015837675,GTPL6641,(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine,SCHEMBL74699,(R)-N-2-Propynyl-1-indanamine

Estimated data

Solubilidad: -1.852 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 40.5% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.